---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-102988"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2024-09-26T23:59:59+00:00"
generated_at: "2026-05-31T01:40:11.242966+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics appoints Morgan Conn, Ph.D. as CFO effective Oct 14, 2024

## Summary
- Morgan Conn, formerly CBO of Pharvaris, appointed CFO; effective October 14, 2024.
- Annual base salary of $470,000; target bonus of 40% of base; $100,000 signing bonus.
- Equity award: option to purchase 360,890 shares and RSU covering 60,148 shares.
- Option vests 25% on first anniversary, remainder monthly over 3 years; RSU vests 25% first year, quarterly thereafter.
- Severance includes 9 months salary and COBRA, extended to 12 months upon change in control.

## SEC filing metadata
- accession: 0001104659-24-102988
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2024-09-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465924102988/0001104659-24-102988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465924102988/tm2424946d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-102988
- JSON: https://secwatch.observer/filing/0001104659-24-102988.json
- Plain text: https://secwatch.observer/filing/0001104659-24-102988.txt

## Key facts
- Executive change
  Morgan Conn was appointed as Chief Financial Officer at Century Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On September 26, 2024, the Century Therapeutics, Inc. (the “Company”) announced the appointment of Morgan Conn, Ph.D. to serve as the Company’s Chief Financial Officer, effective October 14, 2024 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850119/000110465924102988/0001104659-24-102988-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.